Hydralazine tablet overdosage: Difference between revisions
Jump to navigation
Jump to search
(Created page with "__NOTOC__ {{Hydralazine}} {{CMG}}; {{AE}} {{AK}} <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = HYDRALAZINE HYDROCHLORIDE TABLET [PLIVA INC.]...") |
(No difference)
|
Revision as of 19:01, 10 March 2014
Hydralazine |
---|
HYDRALAZINE tablet® FDA Package Insert |
Indications and Usage |
Dosage and Administration |
Contraindications |
Warnings |
Precautions |
Adverse Reactions |
Drug Interactions |
Use in Specific Populations |
Overdosage |
Description |
Clinical Pharmacology |
Nonclinical Toxicology |
How Supplied/Storage and Handling |
Labels and Packages |
HYDRALAZINE injection® FDA Package Insert |
Indications and Usage |
Dosage and Administration |
Contraindications |
Warnings |
Precautions |
Adverse Reactions |
Drug Interactions |
Use in Specific Populations |
Overdosage |
Description |
Clinical Pharmacology |
Nonclinical Toxicology |
How Supplied/Storage and Handling |
Labels and Packages |
Clinical Trials on Hydralazine |
ClinicalTrials.gov |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Abdurahman Khalil, M.D. [2]
References
- ↑ "HYDRALAZINE HYDROCHLORIDE TABLET [PLIVA INC.]". Retrieved 10 March 2014.